IQVIA Holdings Inc. (IQV) KPIs and segments
Close on Nov 18, 2026Market cap $42.49BP/E 31.3Yield –
KPI & bộ phận
Chỉ số vận hành và bộ phận làm nên hoạt động của Iqvia · năm tài chính kết thúc ngày 31 tháng 12
Nhìn nhanh KPI của Iqvia: 42 chỉ số vận hành, trong đó có R&D Solutions Contracted Backlog, Quarterly R&D Solutions Net New Bookings và Quarterly Contracted Net Book-to-Bill Ratio, lấy từ 176 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.
Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.
Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.
| Thêm vào biểu đồ | Chỉ số | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Research & Development Solutions($M)3 | 2,639 | 2,575 | 2,397 | 1,846 | 2,427 | 2,366 | 2,257 | 2,123 | 2,162 | 2,147 | 2,095 | 2,151 | |
Americas($M) | 1,193 | 1,144 | 1,128 | 866 | 1,112 | 1,110 | 1,017 | 925 | 969 | 1,014 | 986 | 1,175 | |
Europe and Africa($M) | 739 | 722 | 667 | 399 | 642 | 601 | 631 | 605 | 607 | 557 | 535 | 556 | |
Asia-Pacific($M) | 707 | 709 | 602 | 581 | 673 | 655 | 609 | 593 | 586 | 576 | 574 | 420 | |
Commercial Solutions($M)3 | 1,789 | 1,793 | 1,754 | 1,673 | 1,651 | 1,572 | |||||||
Americas($M) | 894 | 895 | 856 | 821 | 825 | 790 | |||||||
Europe and Africa($M) | 678 | 687 | 688 | 655 | 640 | 593 | |||||||
Asia-Pacific($M) | 217 | 211 | 210 | 197 | 186 | 189 | |||||||
Technology And Analytics Solutions($M)3 | 1,789 | 1,730 | 1,631 | 1,628 | 1,546 | 1,658 | 1,554 | 1,495 | 1,453 | 1,531 | |||
Americas($M) | 894 | 927 | 824 | 830 | 783 | 859 | 797 | 783 | 743 | 823 | |||
Europe and Africa($M) | 678 | 758 | 652 | 646 | 617 | 640 | 626 | 569 | 562 | 550 | |||
Asia-Pacific($M) | 217 | 45 | 155 | 152 | 146 | 159 | 131 | 143 | 148 | 158 | |||
Contract Sales & Medical Solutions($M)3 | 210 | 209 | 188 | 181 | 177 | 180 | 172 | 189 | 186 | ||||
Europe and Africa($M) | 78 | 75 | 60 | 53 | 53 | 54 | 52 | 60 | 54 | ||||
Americas($M) | 69 | 70 | 68 | 70 | 69 | 72 | 66 | 73 | 76 | ||||
Asia-Pacific($M) | 63 | 64 | 60 | 58 | 55 | 54 | 54 | 56 | 56 | ||||
Americas($M) | 2,087 | 2,039 | 1,984 | 2,070 | 1,933 | 1,935 | 1,807 | 1,853 | 1,838 | 1,863 | 1,802 | 2,074 | |
Europe and Africa($M) | 1,417 | 1,409 | 1,355 | 1,423 | 1,297 | 1,241 | 1,224 | 1,298 | 1,287 | 1,178 | 1,157 | 1,160 | |
Asia-Pacific($M) | 924 | 920 | 812 | 871 | 870 | 841 | 798 | 807 | 771 | 773 | 778 | 634 | |
Research & Development Solutions($M) | 571 | 526 | 472 | 402 | 522 | 473 | 476 | 478 | 498 | 493 | 479 | 524 | |
Commercial Solutions($M) | 410 | 419 | 381 | 357 | 379 | 355 | |||||||
Technology And Analytics Solutions($M) | 410 | 504 | 370 | 389 | 360 | 421 | 405 | 361 | 335 | 404 | |||
Contract Sales & Medical Solutions($M) | 12 | 13 | 12 | 11 | 13 | 12 | 9 | 13 | 12 | ||||
Remaining performance obligations (RPO)($M) | 34,200 | 36,400 | 37,300 | 34,400 | 34,600 | 34,900 | 33,300 | 32,800 | 33,000 | ||||
R&D Solutions Contracted Backlog($M)1 | 32,600 | 34,200 | 34,200 | 32,700 | 32,400 | 32,100 | 31,500 | 31,100 | 31,100 | 30,600 | 30,100 | 29,700 | |
Next 12 Months (NTM) Revenue Expected from Backlog($M)1 | 9,400 | 9,200 | 8,900 | 8,300 | 8,100 | 8,100 | 7,900 | 7,900 | 7,800 | 7,800 | 7,700 | 7,500 | |
Next 12 Months Backlog Conversion Growth (YoY)(%) | 10.0% | 7.5% | 7.6% | 4.0% | 4.8% | ||||||||
Quarterly R&D Solutions Net New Bookings($M) | 3,200 | 3,150 | 2,500 | 2,600 | 2,500 | 2,100 | 2,300 | 2,700 | 2,600 | ||||
Quarterly Contracted Net Book-to-Bill Ratio(×)1 | 1.20 | 1.22 | 1.04 | 1.18 | 1.15 | 1.12 | 1.02 | 1.20 | 1.06 | 1.27 | 1.23 | 1.31 | |
Trailing 12-Month (LTM) Contracted Net Book-to-Bill Ratio(×) | 1.11 | 1.12 | 1.12 | 1.10 | 1.14 | 1.19 | 1.22 | 1.26 | 1.26 | 1.28 | |||
ASC 606 Remaining Performance Obligations (RPO)($M) | 34,200 | 36,400 | 37,300 | 34,200 | 34,400 | 34,600 | 34,900 | 33,500 | 33,300 | 32,800 | 33,000 | 31,700 | |
Unearned Income (Contract Liabilities)($M)2 | 2,313 | 2,281 | 2,261 | 2,118 | 2,160 | 2,123 | 1,940 | 1,779 | 1,824 | 1,811 | 1,914 | 1,799 | |
Unbilled Services (Contract Assets & Unbilled Receivables)($M)1 | 1,741 | 1,769 | 1,763 | 1,783 | 1,891 | 1,896 | 1,896 | 1,856 | 2,061 | 1,938 | 2,019 | 1,942 | |
Unbilled Receivables Share of Unbilled Services(%) | 73.0% | 75.0% | 73.0% | 71.0% | 68.0% | 68.0% | 69.0% | 69.0% | 67.0% | 69.0% | 67.0% | 68.0% | |
Net Contract Balance (Unbilled Services Less Unearned Income)($M) | -572 | -512 | -498 | -335 | -269 | -227 | -44 | 77 | 237 | 127 | 105 | 143 | |
Consolidated Revenue Growth — Reported (YoY)(%)1 | 8.0% | 8.7% | 8.4% | 10.3% | 5.2% | 5.3% | 2.5% | 2.3% | 4.3% | 2.3% | 2.3% | 3.5% | |
Consolidated Revenue Growth — Constant Currency (YoY)(%) | 8.6% | 8.5% | 6.0% | 8.1% | 3.9% | 3.6% | 3.5% | 3.0% | 4.2% | 3.5% | 2.9% | 2.6% | |
Research & Development Solutions — Segment Revenue($M)4 | 2,639 | 2,575 | 2,397 | 1,846 | 2,427 | 2,366 | 2,257 | 2,123 | 2,162 | 2,147 | 2,095 | 2,151 | |
R&D Solutions Revenue Growth — Reported (YoY)(%) | 8.7% | 8.8% | 6.2% | 9.9% | 4.5% | 2.5% | -0.3% | -1.3% | -1.9% | -2.4% | 3.4% | 4.5% | |
R&D Solutions Revenue Growth — Constant Currency (YoY)(%) | 9.1% | 8.6% | 4.2% | 8.2% | 3.4% | 1.3% | 1.1% | 1.0% | 2.0% | 3.3% | 3.8% | 3.7% | |
R&D Solutions — Cost of Revenues (Exclusive of D&A, ASU 2023-07)($M) | 1,811 | 1,801 | 1,675 | 1,259 | 1,662 | 1,652 | 1,551 | 1,430 | 1,442 | 1,431 | 1,395 | 1,416 | |
R&D Solutions — Selling, General & Administrative Expenses (ASU 2023-07)($M) | 257 | 248 | 250 | 185 | 243 | 241 | 230 | 215 | 222 | 223 | 221 | 211 | |
Commercial Solutions — Segment Revenue (Recast Effective Q1 2026)($M)4 | 1,789 | 1,793 | 1,754 | 1,673 | 1,651 | 1,572 | |||||||
Commercial Solutions Revenue Growth — Reported (YoY)(%) | 6.9% | 8.6% | 11.6% | ||||||||||
Commercial Solutions Revenue Growth — Constant Currency (YoY)(%) | 7.9% | 8.4% | 8.5% | ||||||||||
Commercial Solutions — Cost of Revenues (Exclusive of D&A, ASU 2023-07)($M) | 1,119 | 1,132 | 1,121 | 1,065 | 1,042 | 980 | |||||||
Commercial Solutions — Selling, General & Administrative Expenses (ASU 2023-07)($M) | 260 | 242 | 252 | 251 | 230 | 237 | |||||||
Technology & Analytics Solutions — Segment Revenue (Legacy through FY2025)($M)4 | 1,730 | 1,631 | 1,628 | 1,546 | 1,658 | 1,554 | 1,495 | 1,453 | 1,531 | ||||
TAS Revenue Growth — Reported (YoY, Legacy through Q4 2025)(%) | 9.8% | 5.0% | 8.9% | -6.4% | -8.3% | -8.6% | -2.7% | 0.6% | 2.1% | ||||
TAS Revenue Growth — Constant Currency (YoY, Legacy through Q4 2025)(%) | 7.1% | 3.3% | 6.8% | 7.6% | 9.5% | 8.2% | 3.8% | 1.0% | 1.3% | ||||
TAS — Cost of Revenues (Exclusive of D&A, Legacy through FY2025)($M) | 989 | 1,014 | 1,009 | 949 | 1,001 | 922 | 909 | 889 | 903 | ||||
TAS — Selling, General & Administrative Expenses (Legacy through FY2025)($M) | 237 | 247 | 230 | 237 | 236 | 227 | 225 | 229 | 224 | ||||
Contract Sales & Medical Solutions — Segment Revenue (Legacy through FY2025)($M)4 | 210 | 209 | 188 | 181 | 177 | 180 | 172 | 189 | 186 | ||||
CSMS Revenue Growth — Reported (YoY, Legacy through Q4 2025)(%) | 18.6% | 16.1% | 9.3% | -4.2% | -4.8% | -1.6% | -2.3% | 3.8% | 2.2% | ||||
CSMS Revenue Growth — Constant Currency (YoY, Legacy through Q4 2025)(%) | 15.3% | 13.9% | 6.4% | 2.1% | 3.2% | 1.1% | 2.8% | 7.1% | 1.7% | ||||
CSMS — Cost of Revenues (Exclusive of D&A, Legacy through FY2025)($M) | 181 | 181 | 162 | 156 | 149 | 154 | 148 | 160 | 159 | ||||
CSMS — Selling, General & Administrative Expenses (Legacy through FY2025)($M) | 17 | 15 | 14 | 14 | 15 | 14 | 15 | 16 | 15 | ||||
Total Segment Profit($M)2 | 981 | 945 | 853 | 954 | 879 | 852 | 831 | 912 | 915 | 863 | 827 | ||
Unallocated Corporate & Shared Service Expenses($M) | 52 | 84 | 0 | -14 | 20 | 38 | 41 | -13 | 59 | 46 | 42 | 106 | |
Total Segment Selling, General & Administrative Expenses($M) | 517 | 490 | 502 | 482 | 494 | 471 | 467 | 466 | 463 | 463 | 466 | ||
Americas — Consolidated Revenue($M) | 2,087 | 2,039 | 1,984 | 2,070 | 1,933 | 1,935 | 1,807 | 1,853 | 1,838 | 1,863 | 1,802 | 2,074 | |
Total Global Employees | 95,000 | 94,000 | 93,000 | 91,000 | 90,000 | 89,000 | 88,000 | 88,000 | 87,000 | ||||
Adjusted EBITDA($M)4 | 1,032 | 994 | 932 | 1,046 | 949 | 910 | 883 | 996 | 939 | 887 | 862 | 966 | |
Trailing 12-Month (LTM) Adjusted EBITDA($M) | 4,004 | 3,921 | 3,837 | 3,788 | 3,738 | 3,728 | 3,705 | 3,684 | 3,654 | 3,603 | 3,580 | 3,569 | |
Restructuring & Related Expenses (Adjusted EBITDA Add-Back)($M) | 41 | 67 | 53 | 33 | 30 | 42 | 42 | 7 | 38 | 39 | 22 | 24 | |
Acquisition-Related Expenses (Adjusted EBITDA Add-Back)($M) | 8 | 10 | 11 | 1 | 15 | 8 | 8 | 8 | 7 | 10 | 4 | 73 | |
Stock-Based Compensation Expense (Adjusted EBITDA Add-Back)($M) | 83 | 95 | 65 | 60 | 55 | 60 | 72 | 48 | 54 | 48 | 56 | 45 | |
Adjusted Net Income($M)6 | 557 | 527 | 492 | 588 | 515 | 486 | 479 | 564 | 523 | 487 | 468 | 523 | |
Adjusted Pre-Tax Income($M) | 683 | 648 | 599 | 715 | 625 | 593 | 589 | 689 | 643 | 600 | 572 | 640 | |
Adjusted Tax Expense($M) | 124 | 119 | 106 | 127 | 109 | 107 | 110 | 125 | 120 | 113 | |||
Purchase Accounting Amortization (Pre-Tax Reconciliation Add-Back)($M) | 163 | 136 | 137 | 149 | 138 | 131 | 125 | 138 | 139 | 133 | 129 | 149 | |
Adjusted Diluted Earnings per Share($) | 3.34 | 3.15 | 2.90 | 3.42 | 3 | 2.81 | 2.70 | 3.12 | 2.84 | 2.64 | 2.54 | 2.84 | |
Adjusted Basic Earnings per Share($) | 3.38 | 3.17 | 2.92 | 3.46 | 3.03 | 2.83 | 2.73 | 3.15 | 2.87 | 2.67 | 2.57 | 2.88 | |
Non-GAAP Free Cash Flow (Form 8-K)($M) | 667 | 360 | 491 | 561 | 772 | 292 | 426 | 721 | 571 | 445 | 377 | 568 | |
Net Debt (Form 8-K Leverage Table)($M)3 | 13,818 | 14,090 | 13,886 | 13,744 | 13,143 | 13,451 | 12,590 | 12,281 | 11,940 | 11,713 | 12,092 | 12,297 | |
Gross Debt (Form 8-K Leverage Table)($M) | 16,067 | 15,999 | 15,833 | 15,724 | 14,957 | 15,490 | 14,330 | 13,983 | 13,512 | 13,258 | 13,536 | 13,673 | |
Gross Leverage Ratio (Gross Debt / LTM Adjusted EBITDA)(×) | 4.01 | 4.08 | 4.13 | 4.15 | 4.00 | 4.16 | 3.87 | 3.80 | 3.70 | 3.68 | 3.78 | 3.83 | |
Net Leverage Ratio (Net Debt / LTM Adjusted EBITDA)(×) | 3.45 | 3.59 | 3.62 | 3.63 | 3.52 | 3.61 | 3.40 | 3.33 | 3.27 | 3.25 | 3.38 | 3.45 | |
Remaining Share Repurchase Authorization($M) | 2,819 | 2,819 | 1,217 | 1,981 | 1,981 | 2,588 | 2,163 | 2,363 | 2,363 | ||||
Goodwill — Research & Development Solutions($M)3 | 3,819 | 3,691 | 3,622 | 3,629 | 3,032 | 2,716 | 2,615 | 2,608 | 2,625 | 2,431 | 2,433 | 2,439 | |
Goodwill — Commercial Solutions (Recast Post-Q1 2026)($M) | 13,081 | 12,913 | 12,922 | 12,987 | |||||||||
Goodwill — Technology & Analytics Solutions (Legacy through FY2025)($M) | 13,424 | 12,748 | 12,746 | 12,265 | 11,957 | 12,314 | 11,900 | 11,935 | 11,976 | ||||
Goodwill — Contract Sales & Medical Solutions (Legacy through FY2025)($M) | 167 | 168 | 149 | 147 | 145 | 152 | 146 | 148 | 152 | ||||
Severance & Employee Termination Restructuring Reserve($M) | 61 | 67 | 43 | 31 | 33 | 34 | 28 | 21 | 46 | 42 | 34 | 36 | |
Peer Benchmark: ICON plc (ICLR) — Remaining Performance Obligations / Backlog($M)11 | 16,400 | 15,700 | 15,000 | 14,900 | 14,000 | 14,400 | 15,500 | 15,900 | 15,500 | 15,800 | 15,300 | 14,800 | |
ICON plc (ICLR) — Consolidated Revenue($M) | 2,025 | 2,063 | 2,034 | 2,084 | 2,039 | 2,015 | 2,042 | 2,042 | 2,043 | ||||
ICON plc (ICLR) — Operating Income($M) | 199 | 138 | 174 | -223 | 231 | 227 | 303 | 157 | 242 | ||||
Medpace Holdings (MEDP) — Remaining Performance Obligations($M) | 3,800 | 3,500 | 3,500 | 3,600 | 3,500 | 3,500 | 3,400 | 3,500 | 3,500 | 3,200 | 3,200 | 2,900 | |
Medpace Holdings (MEDP) — Consolidated Revenue($M) | 716 | 707 | 707 | 660 | 603 | 559 | 533 | 528 | 511 | ||||
Medpace Holdings (MEDP) — Operating Income($M) | 166 | 147 | 142 | 142 | 126 | 114 | 112 | 105 | 104 | ||||
Charles River Laboratories (CRL) — Remaining Performance Obligations($M) | 675 | 700 | 702 | 667 | 649 | 727 | 782 | 788 | 804 | 857 | 920 | 986 | |
Charles River Laboratories (CRL) — Consolidated Revenue($M) | 983 | 1,004 | 996 | 1,005 | 1,032 | 984 | 1,010 | 1,026 | 1,012 | ||||
Charles River Laboratories (CRL) — Operating Income($M) | 203 | 120 | 120 | 134 | 100 | 75 | 117 | 152 | 126 | ||||
Fortrea Holdings (FTRE) — Remaining Performance Obligations($M) | 4,391 | 4,442 | 4,616 | 4,632 | 4,548 | 4,475 | 4,492 | 4,430 | 4,491 | 4,357 | 4,302 | 4,763 | |
Fortrea Holdings (FTRE) — Consolidated Revenue($M) | 692 | 678 | 636 | 701 | 710 | 651 | 675 | 662 | 662 | ||||
Fortrea Holdings (FTRE) — Operating Income($M) | 15 | 15 | -3 | -9 | -330 | -520 | -18 | -51 | -37 | ||||
U.S. Payrolls: Management, Scientific & Technical Consulting (BLS NAICS 5416)10 | 1,888,400 | 1,887,900 | 1,875,200 | 1,871,600 | 1,860,000 | 1,858,700 | 1,864,300 | 1,880,000 | 1,857,300 | 1,861,700 | 1,856,000 | 1,864,300 | |
U.S. Payrolls: Computer Systems Design & Related Services (BLS NAICS 5415) | 2,350,900 | 2,368,300 | 2,369,600 | 2,380,600 | 2,387,600 | 2,399,900 | 2,408,900 | 2,431,400 | 2,437,600 | 2,444,700 | 2,439,800 | 2,449,800 | |
U.S. Payrolls: Professional & Technical Services (BLS NAICS 54) | 10,848,400 | 10,833,600 | 10,795,600 | 10,784,600 | 10,760,600 | 10,768,000 | 10,782,300 | 10,813,900 | 10,795,000 | 10,820,600 | 10,790,100 | 10,800,100 | |
U.S. Average Hourly Earnings: Professional & Business Services ($/hr)($) | 46.10 | 45.63 | 45.28 | 44.96 | 44.74 | 44.21 | 43.67 | 43.31 | 42.70 | 42.19 | 41.68 | 41.18 | |
U.S. PPI: Pharmaceutical Preparation Manufacturing (BLS NAICS 325412, Index)(×) | 929.25 | 926.18 | 926.04 | 919.30 | 918.73 | 914.85 | 916.46 | 918.46 | 918.07 | 913.98 | 908.96 | 896.41 | |
U.S. PPI: In-Vitro Diagnostic Substance Manufacturing (BLS NAICS 325413, Index)(×) | 300.64 | 300.62 | 303.92 | 300.52 | 299.75 | 297.66 | 291.67 | 284.50 | 284.44 | 284.62 | 284.52 | 284.15 | |
U.S. PPI: Management Consulting Services (BLS Index)(×) | 127.25 | 136.26 | 137.72 | 130.44 | 134.56 | 135.96 | 136.51 | 134.88 | 134.38 | 137.89 | 132.66 | 132.96 | |
U.S. PPI: Computing Infrastructure, Data Processing & Hosting (BLS Index)(×) | 127.44 | 124.04 | 123.04 | 123.64 | 123.94 | 123.66 | 121.88 | 119.35 | 119.62 | 119.64 | 119.25 | 119.03 | |
USD / EUR Monthly Spot Exchange Rate (Federal Reserve H.10)(×) | 1.15 | 1.15 | 1.16 | 1.17 | 1.17 | 1.15 | 1.08 | 1.05 | 1.11 | 1.08 | 1.09 | 1.09 | |
USD / GBP Monthly Spot Exchange Rate (Federal Reserve H.10)(×) | 1.34 | 1.33 | 1.33 | 1.34 | 1.35 | 1.36 | 1.29 | 1.26 | 1.32 | 1.27 | 1.27 | 1.27 | |
JPY / USD Monthly Spot Exchange Rate (Federal Reserve H.10)(×) | 156.42 | 160.77 | 158.68 | 155.91 | 147.86 | 144.48 | 149.06 | 153.81 | 142.95 | 157.86 | 149.82 | 143.98 | |
Consolidated Revenue (GAAP)($M)10 | 4,428 | 4,368 | 4,151 | 4,364 | 4,100 | 4,017 | 3,829 | 3,958 | 3,896 | 3,814 | 3,737 | 3,868 | |
Cost of Revenue (Exclusive of D&A)($M) | 2,930 | 2,933 | 2,796 | 2,928 | 2,727 | 2,694 | 2,531 | 2,580 | 2,518 | 2,488 | 2,444 | 2,478 | |
Selling, General & Administrative Expenses($M) | 569 | 574 | 502 | 468 | 514 | 509 | 508 | 453 | 522 | 509 | 508 | 556 | |
Restructuring Costs($M) | 36 | 63 | 51 | 24 | 20 | 32 | 29 | -4 | 28 | 28 | 15 | 17 | |
Operating Income (GAAP)($M) | 572 | 506 | 514 | 627 | 553 | 506 | 496 | 626 | 550 | 520 | 506 | 501 | |
Interest Expense($M) | 203 | 197 | 192 | 193 | 189 | 182 | 165 | 171 | 170 | 163 | 166 | 181 | |
Income Before Income Taxes($M) | 386 | 301 | 328 | 537 | 408 | 323 | 323 | 544 | 349 | 436 | 340 | 373 | |
Income Tax Expense($M) | 76 | 60 | 59 | 59 | 76 | 56 | 61 | 112 | 65 | 75 | 49 | -102 | |
Net Income Attributable to IQVIA (GAAP)($M) | 350 | 256 | 274 | 514 | 331 | 266 | 249 | 437 | 285 | 363 | 288 | 469 | |
Diluted Earnings per Share (GAAP)($) | 2.10 | 1.53 | 1.61 | 1.93 | 1.54 | 1.40 | 1.55 | 1.97 | 1.56 | ||||
Weighted Average Diluted Shares(M) | 167 | 167 | 170 | 172 | 173 | 177 | 184 | 184 | 184 | ||||
Total Assets($M)8 | 30,474 | 29,881 | 29,675 | 29,944 | 28,727 | 28,632 | 27,322 | 26,899 | 27,180 | 26,398 | 26,574 | 26,681 | |
Cash and Cash Equivalents($M) | 2,249 | 1,909 | 1,947 | 1,980 | 1,814 | 2,039 | 1,740 | 1,702 | 1,572 | 1,545 | 1,444 | 1,376 | |
Accounts Receivable and Unbilled Services, Net($M) | 3,293 | 3,345 | 3,346 | 3,400 | 3,269 | 3,344 | 3,268 | 3,204 | 3,196 | 3,255 | 3,426 | 3,381 | |
Unearned Income (Current Deferred Revenue)($M) | 2,313 | 2,281 | 2,261 | 2,118 | 2,160 | 2,123 | 1,940 | 1,779 | 1,824 | 1,811 | 1,914 | 1,799 | |
Property, Equipment and Software, Net($M) | 534 | 547 | 516 | 533 | 525 | 536 | 533 | 535 | 513 | 503 | 513 | 523 | |
Goodwill($M) | 16,900 | 16,604 | 16,544 | 16,616 | 15,948 | 15,611 | 15,027 | 14,710 | 15,091 | 14,477 | 14,516 | 14,567 | |
Other Identifiable Intangible Assets, Net($M) | 4,738 | 4,749 | 4,803 | 4,962 | 4,707 | 4,596 | 4,503 | 4,499 | 4,734 | 4,608 | 4,725 | 4,839 | |
Total Liabilities($M) | 23,683 | 23,580 | 23,326 | 23,314 | 22,439 | 22,846 | 21,337 | 20,832 | 20,213 | 19,684 | 20,230 | 20,569 | |
Stockholders' Equity($M) | 6,660 | 6,171 | 6,221 | 6,503 | 6,160 | 5,778 | 5,977 | 6,067 | 6,967 | 6,714 | 6,344 | 6,112 | |
Operating Cash Flow (GAAP)($M)5 | 825 | 558 | 618 | 735 | 908 | 443 | 568 | 885 | 721 | 588 | 522 | 747 | |
Capital Expenditures (Additions to Property, Equipment & Software)($M) | 158 | 198 | 127 | 174 | 136 | 151 | 142 | 164 | 150 | 143 | 145 | 179 | |
Depreciation and Amortization($M) | 321 | 292 | 288 | 317 | 286 | 276 | 265 | 303 | 278 | 269 | 264 | 316 | |
Stock-Based Compensation (Cash Flow)($M) | 83 | 95 | 65 | 60 | 55 | 60 | 72 | 48 | 54 | 48 | 56 | 45 | |
Business Acquisitions, Net of Cash Acquired($M) | 389 | 163 | 37 | 916 | 483 | 181 | 134 | 86 | 428 | 79 | 142 | 7 | |
Repurchases of Common Stock (Cash Flow)($M) | 0 | 398 | 552 | 212 | 0 | 657 | 375 | 1,150 | 200 | 0 | 0 | 229 | |
16 chỉ số không có số liệu trong 12 quý gần nhất — .
In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).
Phương pháp và các chỉ số bị loại
- Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
- Latest reported company period: Q3 2026 (ended September 30, 2026; Form 8-K filed October 27, 2026 and Form 10-Q filed October 29, 2026) and full fiscal year FY2025 (ended December 31, 2025; Form 10-K filed February 18, 2026).
- Primary operational metrics for IQVIA's clinical research and healthcare intelligence business are R&D Solutions Contracted Backlog ($32.6B at Q3 2026 following a $2.1B adjustment for trials inactive >18 months), Next-12-Month Expected Backlog Revenue Conversion ($9.4B at Q3 2026, +10.0% YoY), Quarterly & LTM Net New Bookings ($3.2B in Q3 2026; $11.7B LTM, +14% YoY), Quarterly & LTM Contracted Net Book-to-Bill Ratio (1.20x in Q3 2026), and ASC 606 Remaining Performance Obligations ($34.2B at Q3 2026).
- Segment Reorganization (Effective Q1 2026): IQVIA combined its former Technology & Analytics Solutions (TAS) and Contract Sales & Medical Solutions (CSMS) segments into a single Commercial Solutions segment alongside Research & Development Solutions (R&DS). Both the recast Commercial Solutions series (Q1 2025 – Q3 2026) and the legacy TAS and CSMS series (through Q4 2025 / FY2025) are presented, including segment Cost of Revenues and segment SG&A disclosed under ASU 2023-07.
- Standalone vs. Consolidated Assessment: IQVIA Holdings Inc. files only U.S. GAAP consolidated financial statements with the SEC and omits parent-only Schedule I under Regulation S-X Rule 5-04 because restricted net assets of subsidiaries do not exceed 25% of consolidated net assets; therefore, consolidated-minus-standalone parent subtraction is not applicable. Instead, 6 years (FY2020–FY2025) of audited UK statutory accounts (FRS 101, in £ thousands) for IQVIA Ltd. (UK Companies House #03022416, £3.04B FY2025 turnover, 3,894 employees) are presented in a dedicated group.
- All figures are strictly as reported (with verbatim source quotes attached to text-extracted values; inequality-bounded marketing claims are excluded). The only arithmetic applied is cumulative period splitting (Q4 = full year − nine months; quarterly = year-to-date − prior year-to-date), marked with its formula.
Không hiện vì thiếu các kỳ gần đây (18)
- R&D Solutions — Clinical Backlog, Net New Bookings & Book-to-Bill › Quarterly R&D Solutions Net New Bookings › Trailing 12-Month (LTM) R&D Solutions Net New Bookings
- UK Statutory Gender Pay Gap Disclosures across Operating Entities › Global Total Market-Based GHG Emissions (Scope 1, 2 & 3, tCO2e) › Global Scope 1 Direct GHG Emissions (tCO2e)
- UK Statutory Gender Pay Gap Disclosures across Operating Entities › Global Total Market-Based GHG Emissions (Scope 1, 2 & 3, tCO2e) › Global Scope 2 Location-Based GHG Emissions (tCO2e)
- UK Statutory Gender Pay Gap Disclosures across Operating Entities › Global Total Market-Based GHG Emissions (Scope 1, 2 & 3, tCO2e) › Global Scope 2 Market-Based GHG Emissions (tCO2e)
- UK Statutory Gender Pay Gap Disclosures across Operating Entities › Global Total Market-Based GHG Emissions (Scope 1, 2 & 3, tCO2e) › Global Scope 3 Value-Chain GHG Emissions (tCO2e)
- UK Statutory Gender Pay Gap Disclosures across Operating Entities › Global Total Market-Based GHG Emissions (Scope 1, 2 & 3, tCO2e) › Global Scope 1 & 2 Energy Consumption (MWh)
- UK Statutory Gender Pay Gap Disclosures across Operating Entities › Global Total Market-Based GHG Emissions (Scope 1, 2 & 3, tCO2e) › Women Share of Global Workforce
- UK Statutory Gender Pay Gap Disclosures across Operating Entities › Global Total Market-Based GHG Emissions (Scope 1, 2 & 3, tCO2e) › Women Share of Global People Managers
- UK Statutory Gender Pay Gap Disclosures across Operating Entities › Global Total Market-Based GHG Emissions (Scope 1, 2 & 3, tCO2e)
- Consolidated Financial Statement Context (GAAP Reference) › Consolidated Revenue (GAAP) › Gross Profit
- Non-Identified Patient Records ('more than 1.2 billion comprehensive, longitudinal, non-identified patient records' in Form 10-K Item 1) — inequality-bounded figure ('more than').
- Total Countries of Operation ('operations in more than 100 countries' in Form 10-K Item 1) — inequality-bounded figure; exact physical office country count (~80–82 countries in Item 2) is included instead.
- Technology & Analytics Solutions Headcount ('over 25,000 technology, analytics, and consulting professionals' in Form 10-K Item 1) — inequality-bounded figure in recent Form 10-Ks.
- Clinical Trial Sites & Investigators ('more than 50,000 clinical trial sites' in ESG/IR narratives) — inequality-bounded marketing figure.
- Q4 2024 and Q4 2025 Quarterly R&D Solutions Net New Bookings ('over $2.5 billion' and 'over $2.7 billion' in Form 8-K) — inequality-bounded text figures excluded from the quarterly bookings series.
- Organic Revenue Growth Rates on Earnings Calls (e.g., Q3 2026 ~6% consolidated organic growth, ~7% R&DS, ~4% Commercial Solutions) — disclosed intermittently in earnings call remarks without a continuous 3-quarter table in Form 8-K/10-Q.
- Emerging Biopharma (EBP) Share of R&DS Backlog / RFP Dollars (~10% pre-commercial EBP share in Q1–Q2 2022 calls; $33B EBP industry funding in Q4 2025 call) — one-off qualitative call commentary without a continuous series.
- Global Environmental GHG Inventory (Scope 1, 2 & 3 tCO2e and Energy Consumption MWh) & Global Workforce Gender Percentages — latest published IQVIA Sustainability Report covers FY2019–FY2024 only (FY2025 global environmental inventory not yet released; audited 5-year FY2021–FY2025 UK SECR energy & carbon series for IQVIA Ltd. is presented in Group 6).
Dữ liệu cập nhật 2026-11-08.
Mỗi KPI một trang riêng
Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số
R&D Solutions — Clinical Backlog, Net New Bookings & Book-to-Bill
ASC 606 Remaining Performance Obligations & Clinical Contract Balances
Segment Operations, Constant-Currency Growth & Significant Expenses (ASU 2023-07)
- Consolidated Revenue Growth — Reported (YoY) (%)25 kỳ
- Research & Development Solutions — Segment Revenue ($M)39 kỳ
- Commercial Solutions — Segment Revenue (Recast Effective Q1 2026) ($M)8 kỳ
- Technology & Analytics Solutions — Segment Revenue (Legacy through FY2025) ($M)35 kỳ
- Contract Sales & Medical Solutions — Segment Revenue (Legacy through FY2025) ($M)35 kỳ
- Total Segment Profit ($M)24 kỳ
Geographic Disaggregation & Cross-Dimensional Segment × Region Matrix
Healthcare Data Assets, Real Estate Footprint, Workforce & Compensation
IQVIA Ltd. (UK Companies House #03022416 — Audited Statutory Subsidiary Accounts)
Non-GAAP Profitability Reconciliations, Leverage & Share Repurchases
Goodwill by Segment, Identifiable Intangibles, PP&E Classes & Restructuring
UK Statutory Gender Pay Gap Disclosures across Operating Entities
External Clinical Trial Activity, U.S. Federal Awards, Peer CROs & Macro Indicators
- U.S. Federal Contract Obligations Awarded to IQVIA (USAspending.gov) ($M)105 kỳ
- ClinicalTrials.gov Registered Studies Started (IQVIA Sponsor / Collaborator)11 kỳ
- Peer Benchmark: ICON plc (ICLR) — Remaining Performance Obligations / Backlog ($M)35 kỳ
- U.S. Payrolls: Management, Scientific & Technical Consulting (BLS NAICS 5416)105 kỳ
Consolidated Financial Statement Context (GAAP Reference)
Tài liệu nguồn mới nhất
Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Iqvia
- IQVIA Form 10-Q (FY2026Q3, 0001628280-26-067646) ↗
- IQVIA Form 10-K (FY2025, 0001628280-26-008322) ↗
- Form 8-K Item 2.02 (FY2026Q3, 2026-10-27) ↗
- Form 8-K Item 2.02 (FY2025, 2026-02-05) ↗
- IQVIA Ltd. UK Companies House #03022416 Statutory Accounts (uk_03022416_AA_2025.pdf, filed 2026-09-25) ↗
- IQVIA UK Gender Pay Gap Report (2025) ↗
- Federal Reserve Economic Data (FRED / U.S. BLS Series CES6054160001) ↗
- IQVIA Form 10-Q (filed 2026-10-27) ↗
- IQVIA Form 10-K (filed 2026-02-17) ↗
- IQVIA Form 10-K (FY2025, 0001628280-26-008322) & Form 10-Q (FY2024Q3, 0001478242-24-000117) ↗
- Form 20-F / 6-K XBRL (ICON plc, CIK 0001060955) (6-K) ↗
- IQVIA DEF 14A Proxy Statement (2026-02-27, p. 100) ↗
See a number that looks wrong?